Baxter International Inc. ($BAX) Stock Forecast: Down 15.0% Today

What is Baxter International Inc.?

Baxter International Inc. (BAX) recently announced its fourth-quarter 2025 earnings, leading to a bearish market sentiment due to underwhelming financial results and a cautious outlook for 2026.

Why is Baxter International Inc. going down?

BAX stock is down 15.0% on Feb 12, 2026 18:02

• Baxter International Inc. (BAX) saw its stock price plummet by 13.3% to 14.63% in pre-market trading following the earnings announcement.
• The decline in BAX's stock price can be linked to the fourth-quarter earnings falling below analyst expectations, notably with an adjusted EPS of $0.44 missing projections.
• Furthermore, the company's conservative 2026 forecast, with anticipated flat to 1% sales growth and adjusted EPS below consensus estimates, added to investor worries about Baxter's future.
• Despite introducing a new operating model aimed at streamlining its operations and enhancing performance, Baxter's stock experienced a significant drop, overshadowing the efforts to mitigate the impact of the disappointing earnings and outlook.

BAX Price Chart

BAX Technical Analysis

BAX News

BAX Stock Falls Following Q4 Earnings Miss, Margins Contract

Baxter International Inc. (BAX) reported fourth-quarter 2025 adjusted earnings per share of 44 cents, missing analyst estimates by 17%, and revenues of $2.97 billion, which beat estimates. The company's adjusted gross margin contracted significantly by 900 basis points to 35.5%, leading to a 13.3% drop in BAX shares in pre-market trading. Baxter also provided a cautious outlook for 2026, forecasting flat to 1% sales growth and an adjusted EPS range below consensus estimates.

https://www.tradingview.com/news/zacks:355ed35e3094b:0-bax-stock-falls-following-q4-earnings-miss-margins-contract/

Baxter stock dives on Q4 EPS miss, company introduces new operating model

Baxter's stock fell after the company reported Q4 earnings that missed analyst expectations, despite sales exceeding forecasts. The company posted a significant loss and announced a new operating model designed to simplify the organization, accelerate innovation, and improve performance. CEO Andrew Hider expressed confidence in Baxter's long-term trajectory despite the challenging quarter.

https://www.massdevice.com/baxter-stock-dives-q4-2025-miss/

Baxter International Stock Falls Sharply. Earnings Were Brutal.

Baxter International's stock dropped significantly after the medical device company reported earnings that fell short of expectations and provided a bleak forecast for 2026. The company's performance made it one of the S&P 500's worst performers today.

https://www.barrons.com/articles/baxter-international-earnings-stock-price-2108be20?gaa_at=eafs&gaa_n=AWEtsqdxWOUPuPmKwjdQxIOEiTWKc3kv6exH1J1UfLcA1L4eEKK5QVIoBn__&gaa_ts=698e1048&gaa_sig=Ji8uLIbucpAc4HIKPz8YHs2U4xK5lwu7g3BNoz7bGpnNVtU_xvQGm36yE192V9uMy6VbEk9n9WoDRHbndqFcOg%3D%3D

Baxter International Inc (NYSE:BAX) Stock Plummets on Q4 Earnings Miss and Weak 2026 Outlook

Baxter International Inc. reported a Q4 2025 revenue beat but a significant earnings miss, leading to a sharp decline in its stock. The company's adjusted EPS of $0.44 fell short of estimates, and its weak 2026 guidance, projecting flat to 1% reported sales growth and adjusted EPS of $1.85 to $2.05, further alarmed investors. Despite sales growth across all segments, a substantial GAAP loss impacted by goodwill impairment and a cautious outlook for the coming year have raised concerns about the company's profitability and operational turnaround.

https://www.chartmill.com/news/BAX/Chartmill-41860-Baxter-International-Inc-NYSEBAX-Stock-Plummets-on-Q4-Earnings-Miss-and-Weak-2026-Outlook

Baxter Int'l Provides Weak FY26 Outlook As Q4 Adj. EPS Misses Estimates; Stock Tumbles 14.6%

Baxter International, Inc. reported a significant net loss in Q4, missing analysts' adjusted EPS estimates with $0.44 per share against an expected $0.54. Despite an 8% increase in worldwide net sales to $2.97 billion, the company provided a weak fiscal 2026 outlook, projecting adjusted earnings of $1.85 to $2.05 per share, below the Street's expectation of $2.25 per share. Following this news, Baxter's stock (BAX) tumbled 14.63% in pre-market trading.

https://www.nasdaq.com/articles/baxter-intl-provides-weak-fy26-outlook-q4-adj-eps-misses-estimates-stock-tumbles-146

Trending Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 5.1% Today

Iron Mountain Incorporated (Delaware)Common Stock REIT ($IRM) Stock Forecast: Up 5.2% Today

Marathon Petroleum Corporation ($MPC) Stock Forecast: Down 5.2% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Down 5.1% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Down 5.0% Today

Gartner Inc. ($IT) Stock Forecast: Down 5.1% Today

CBRE Group Inc Class A ($CBRE) Stock Forecast: Down 8.3% Today

Lincoln National Corporation ($LNC) Stock Forecast: Up 5.4% Today

HP Inc. ($HPQ) Stock Forecast: Down 5.2% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 7.3% Today

Baxter International Inc. Price History

04.01.2026 - BAX Stock was up 5.2%

• BAX encountered challenges in Q4, such as disappointing Q3 results, a dividend reduction, and delays in IV fluid volume normalization and Novum pump shipments, resulting in underperformance.
• Growth projections in the outpatient oncology infusion market could have a beneficial impact on BAX, given its role in fostering innovation in this area.
• Hospitals opting to phase out desflurane over environmental concerns could indirectly assist BAX, as the transition to eco-friendly alternatives may boost the company's image.
• The announcement of Avidity Biosciences' share distribution and Axogen's recent equity offerings might have positively influenced investor sentiment, contributing to the bullish momentum in BAX's stock.

31.06.2025 - BAX Stock was down 21.0%

• Baxter International Inc. (BAX) experienced a significant bearish movement following its Q2 earnings report, where it missed both earnings and sales expectations.
• The company also revised its full-year EPS outlook downwards, leading to a lack of confidence among investors and a sharp decline in the stock price.
• The weaker gross margin reported by Baxter further added to the negative sentiment, causing shares to slide nearly 9% pre-market.
• The disappointing earnings results and lowered guidance suggest that Baxter may be facing challenges in its core segments, impacting investor perception and leading to the bearish market movement.

12.01.2026 - BAX Stock was down 12.7%

• Baxter International Inc. reported a Q4 earnings miss and provided a weak outlook for 2026, leading to a sharp decline in its stock price.
• Despite revenue exceeding estimates, the company's adjusted EPS fell short, and its projected earnings for the upcoming year were below expectations, causing concern among investors.
• The substantial GAAP loss and cautious guidance for 2026 highlighted potential profitability and operational challenges for the company, contributing to the bearish market movement.
• The stock tumbled as much as 14.63% in pre-market trading following the disappointing financial results and outlook, reflecting investors' apprehensions about Baxter's performance in the near future.

12.01.2026 - BAX Stock was down 15.0%

• Baxter International Inc. (BAX) saw its stock price plummet by 13.3% to 14.63% in pre-market trading following the earnings announcement.
• The decline in BAX's stock price can be linked to the fourth-quarter earnings falling below analyst expectations, notably with an adjusted EPS of $0.44 missing projections.
• Furthermore, the company's conservative 2026 forecast, with anticipated flat to 1% sales growth and adjusted EPS below consensus estimates, added to investor worries about Baxter's future.
• Despite introducing a new operating model aimed at streamlining its operations and enhancing performance, Baxter's stock experienced a significant drop, overshadowing the efforts to mitigate the impact of the disappointing earnings and outlook.

30.09.2025 - BAX Stock was down 14.2%

• There was a downward revision in Baxter International Inc.'s 2025 guidance, resulting in a notable decline in its stock value to a 52-week low.
• Despite exceeding expectations in its third-quarter earnings report, the company's reduced sales and EPS projections for 2025 influenced the negative market sentiment.
• Legal inquiries from Faruqi & Faruqi, LLP and a securities fraud class action lawsuit caution from Bernstein Liebhard LLP potentially heightened investor worries and further impacted the stock's performance.
• The stock faced a bearish trend following the mixed reactions to Baxter's Q3 earnings, which included surpassing earnings but missing sales targets, along with a downward adjustment in its 2025 EPS guidance.

30.09.2025 - BAX Stock was down 17.0%

• A looming deadline for a securities fraud class action lawsuit could have caused unease among investors, triggering a selloff of Baxter International Inc. shares.
• Weaknesses in the IV fluid and anesthesia segments, noted in the Q3 preview, may have raised concerns about the company's future revenue and earnings performance.
• Ongoing shareholder litigations and legal investigations might have heightened the negative sentiment surrounding Baxter International Inc., exerting downward pressure on its stock value.
• In sum, the intertwining factors of legal uncertainties, segment vulnerabilities, and shareholder disputes likely contributed to the bearish market movement witnessed in Baxter International Inc. today.

30.09.2025 - BAX Stock was down 14.8%

• Baxter International Inc. (BAX) surpassed Q3 earnings expectations but missed sales targets, prompting a downward revision of their 2025 EPS guidance.
• Despite positive performances in Pharma and Advanced Surgery, concerns arose among investors due to the overall sales miss and reduced EPS outlook, leading to a bearish market movement.
• The presence of an upcoming securities fraud class action lawsuit deadline and investor alerts may have further fueled negative sentiments around the company, impacting the stock price negatively.
• Investors are focusing on Baxter's core segments, notably Advanced Surgery and Drug Compounding, in the next quarter to evaluate the company's growth prospects in light of challenges faced by other product lines like IV fluids and anesthesia.

21.10.2025 - BAX Stock was up 5.2%

• The multiple class action lawsuits against Baxter International might have initially caused uncertainty and a dip in the stock price.
• However, investors might have regained confidence in the company due to positive developments or reassurances from Baxter International's management.
• This bullish movement could indicate that investors believe the impact of the lawsuits on the company's financials and reputation might be manageable.
• It's possible that some investors see an opportunity in the temporary dip caused by the lawsuits and are now buying the stock at a lower price, contributing to the bullish movement.

15.00.2026 - BAX Stock was up 5.2%

• Baxter International Inc. introduced its Dynamo Series smart stretcher, emphasizing technological innovation in acute care to improve patient safety and hospital workflow efficiency, likely boosting the positive stock movement.
• Despite a decrease in stake by Manning & Napier Advisors LLC, growing interest from other institutional investors and Baxter's focus on connected care solutions may have bolstered market confidence and contributed to the bullish trend.
• Initially trailing behind competitors, Baxter International Inc.'s stock performance saw a shift towards optimism with the launch of the Dynamo Series smart stretcher, influencing the bullish market movement.
• FDA clearance for Medtronic's smart insulin pen app, though unrelated to Baxter, indicates progress in healthcare technology, potentially benefiting companies like Baxter International Inc. through positive market effects.

10.01.2026 - BAX Stock was up 5.3%

• The bullish movement in Baxter International Inc. (BAX) could be attributed to the positive news surrounding the company's commitment to respiratory health for patients, showcasing its dedication to improving patient care and quality of life.
• The downgrades from financial firms may have initially caused some uncertainty in the market, but the strong focus on innovative healthcare solutions and patient support likely reassured investors, leading to the bullish trend.
• The workforce reduction at a plant impacted by Hurricane Helene could have been perceived as a strategic move by Baxter to streamline operations and enhance efficiency, potentially positively impacting the company's bottom line and investor confidence.
• The overall positive sentiment towards Baxter International Inc. (BAX) amid its focus on healthcare innovation and patient support likely contributed to the bullish market movement despite some external challenges and analyst downgrades.

12.10.2025 - BAX Stock was up 5.1%

• Despite the pending class action lawsuits and reminders to shareholders, Baxter International Inc. saw a bullish trend, indicating that investors may have confidence in the company's ability to navigate through legal challenges.
• The market movement could be attributed to positive developments within the company that outweigh the legal uncertainties highlighted in recent discussions.
• Investors might be optimistic about Baxter International's future performance and potential growth prospects in the healthcare industry, leading to increased buying activity and driving the stock price higher.

31.09.2025 - BAX Stock was down 5.4%

• Today's downward trend in Baxter International Inc. (BAX) stock may be linked to the following factors:
• A pending securities fraud class action lawsuit by The Gross Law Firm has caused apprehension among investors, resulting in a decrease in confidence and a sell-off of shares.
• Baxter has revised its annual outlook and lowered its 2025 guidance on multiple occasions, which might have negatively impacted investor sentiment, with the stock hitting a 52-week low after the latest adjustment in guidance.
• Despite Baxter's Q3 earnings surpassing expectations, the stock dropped due to a sales shortfall and a downward revision in the 2025 EPS forecast, suggesting potential challenges in revenue generation ahead.
• Ongoing investigations and shareholder alerts by legal firms like Faruqi & Faruqi, LLP and Bernstein Liebhard LLP have contributed to the overall uncertainty surrounding the company, potentially influencing the bearish market movement.